Wed, Nov 26, 2014, 6:39 AM EST - U.S. Markets open in 2 hrs 51 mins

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • QCRH: Breakout Year Expected in 2015 Zacks Small Cap Research - 21 hours ago

    By Ann Heffron, CFA, CPA  NASDAQ:QCRH We expect 2015 to be a breakout year for QCRH (NASDAQ:QCRH) , and are now estimating a 14% gain in diluted EPS to $2.10, up from $1.93 previously. Click here to download ...

  • This Phase II clinical trial will be a multicenter investigator sponsored trial (IST), with UCSF and Dr. Alain Algazi as the sponsor. Merck will supply pembrolizumab, and OncoSec will provide electroporation devices and plasmid IL-12. Immune checkpoint inhibition is the one of the most promising area for the treatment …

  • CTTC: International Sales Push Revenue To 3-Yr High Zacks Small Cap Research - Mon, Nov 24, 2014 3:30 PM EST

    By Brian Marckx, CFA OTC:CTTC Q3 2014 Results:   Revenue Jumps As Re-Established Int'l Territories Already Making Big Contribution…   Calmare Therapeutics (OTC:CTTC) reported financial results for the ...

  • OMBP: Omni Bio Encouraged By Early-Stage Data At American Heart Association Meeting Zacks Small Cap Research - Fri, Nov 21, 2014 1:00 PM EST

    On November 19, 2014, Omni Bio Pharmaceuticals, Inc. (OMBP) presented data from a Phase 1 clinical trial studying the effects of a single dose of plasma-derived alpha-1 antitrypsin (p-AAT) in ten patients post acute ST-elevation myocardial infarction ("STEMI"). The goal of the study (NCT01936896) was to determine whether …

  • GOVX: GeoVax Reports 2014 Third Quarter Financial Results with Conservative Cash Burn Zacks Small Cap Research - Fri, Nov 21, 2014 10:00 AM EST

    These revenues were related to grants from the NIH in support of its HIV/AIDS vaccine development efforts. R&D expenses include direct costs funded by NIH grants, as well as vaccine manufacturing and testing costs and expenses related to the Company’s HIV immunotherapy program. As of September 30, 2014, GeoVax held a …

  • SANW: Entering the Republic of Turkey with alfalfa seed sales to a distributor. Zacks Small Cap Research - Fri, Nov 21, 2014 9:00 AM EST

    S&W Seed (SANW) announced on Nov. 20, 2014 that it has made its first sale to a distributor in the Republic of Turkey. The company is likely to expand the number of distributors in Turkey as part of its strategy of geographical diversification. The initial sales will be of seed varieties already registered in Turkey by …

  • FPMI: CardioPET Data A Catalyst to Share Price Appreciation Zacks Small Cap Research - Thu, Nov 20, 2014 2:15 PM EST

    By Brian Marckx, CFA OTC:FPMI We have updated our report on FluoroPharma Medical (OTC:FPMI).  See below for free access to our full report on the company.    Development of FluoroPharma's CardioPET nuclear ...

  • ADXS: New Jersey Technology Business Tax Program Grants Advaxis $1.7M Tax Credit Zacks Small Cap Research - Thu, Nov 20, 2014 11:30 AM EST

    By Anthony Schwartz, PhD NASDAQ:ADXS Advaxis (NASDAQ:ADXS), a clinical stage biopharmaceutical company, announced on November 20, 2014 that the New Jersey Technology Business Tax Certificate Transfer (NOL) ...

  • Dejour Energy: 3rd Quarter Results, Woodrush/Hunter Project Update Zacks Small Cap Research - Thu, Nov 20, 2014 8:00 AM EST

    Dejour Energy (DEJ.TO) (DEJ) reported results for the third quarter ending September 30, 2014. Gross oil and gas revenues (before royalties) declined 5.9% Year-Over-Year (YOY) to $2.26 million, which was primarily due to the sale of a 65% working interest in the Kokopelli Project (including the four producing natural gas …

  • AMBS: Astute Deal Brings In Another Shot On Goal For Amarantus Bio Zacks Small Cap Research - Wed, Nov 19, 2014 2:30 PM EST

    On November 17, 2014, Amarantus Bioscience Holdings, Inc. (AMBS) announced that it has entered into an exclusive option agreement with Lonza Walkersville, Inc. to acquire Cutanogen Corporation. Both Lonza Walkersville and Cutanogen Corp. are subsidiaries of Lonza Group Ltd. Acquiring Cutanogen gives Amarantus rights to …

  • Cynapsus Set For Major Revaluation On Positive Phase 2 Data Zacks Small Cap Research - Wed, Nov 19, 2014 10:00 AM EST

    On November 19, 2014, Cynapsus Therapeutics Inc. (CYNAF) (CTH.V) announced what looks to be a clear demonstration of proof-of-concept via positive top-line results from the CTH-105 Phase 2 clinical trial. The CTH-105 study was the first to test Cynapsus APL-130277, a fast-acting, sublingual, thin filmstrip formulation …

  • PBIO Reports 14% Product Revenue Growth for 3Q14 Zacks Small Cap Research - Wed, Nov 19, 2014 9:00 AM EST

    Total revenue for 3Q14 was $372,545, compared to $420,762 for the same period in 2013, an 11% decrease.

  • ILIU: Awareness Building, PerioPredict Adoption Growing Zacks Small Cap Research - Tue, Nov 18, 2014 3:45 PM EST

    ILIU further bolstered these efforts over the last few months and scored additional significant recognition.  This included receiving the 2014 DrBiscupid Dental Excellence Award for PerioPredict as the "Best New Hygienist Product" in October and the authors (including ILIU's own Dr. Ken Kornman and Dr. Lynn Doucette-Stamm) …

  • PRGB: Scoring Successes in Product & Svcs Biz Zacks Small Cap Research - Tue, Nov 18, 2014 11:10 AM EST

    By Brian Marckx, CFA   OBB:PRGB Q3 Update: InSphero Partnership Already Bearing Fruit, 2 High-Profile Customers Buy LAESI Systems… Protea Biosciences (OBB:PRGB) filed their 10-Q for the third quarter ending ...

  • CTSO Remains Highly Undervalued Zacks Small Cap Research - Tue, Nov 18, 2014 9:15 AM EST

    CytoSorbents (CTSO) reported results for the third quarter ending September 30, 2014.  The streak of setting a new record in product revenue was extended to seven straight quarters with Q3 product revenue coming in at $1.0 million, an increase of 276% and 56% from Q3 2013 (i.e. Awareness-building to key opinion leaders …

  • Northstar Healthcare reports 3Q; Zacks raises target to $2.54 Zacks Small Cap Research - Tue, Nov 18, 2014 9:00 AM EST

    On November 13, 2014, Northstar Healthcare (NHC.TO) reported financial results for the third quarter ending September 30, 2014. Net patient revenues continue to grow significantly, driven by the company’s marketing campaigns (especially for bariatric procedures) and the contributions from the expanded operational platform, …

  • On November 10, Soligenix (SNGX) reported financial results for the third quarter ended September 30, 2014.

  • ULUR: Quick Look At ULURU's Third Quarter And Business Fundamentals Zacks Small Cap Research - Mon, Nov 17, 2014 3:00 PM EST

    On November 17, 2014, ULURU, Inc. (ULUR) reported financial results and filed its Form 10-Q for the third quarter 2014, which corresponded to the three month period ending September 30, 2014. For example, earlier in November, ULURU, Inc. signed up an exclusive distribution agreement for 17 Middle East and North African …

  • SNWV: Expect DMC Recommendation in Q1 Zacks Small Cap Research - Mon, Nov 17, 2014 10:30 AM EST

    > On September 9th SANUWAVE announced the Data Monitoring Committee (DMC) overseeing data analysis of the company's supplemental dermaPACE trial recommended, following analysis of the first 90 patients (i.e.

  • By Anthony Schwartz, PhD  NASDAQ:THLD Threshold Pharmaceuticals (NASDAQ:THLD)  is a clinical stage biopharmaceutical company currently evaluating its lead compound, TH-302, in several clinical trials for ...

  • 2015 Will Be The Year Nuo Therapeutics Shines Zacks Small Cap Research - Fri, Nov 14, 2014 1:00 PM EST

    On November 13, 2014, Nuo Therapeutics, Inc. (OTC:NUOT) reported financial results for the third quarter ending September 30, 2014. Revenues were driven by $1.20 million in product sales derived from both Angel and Aurix and $0.49 million in licensing fees, royalties, and other revenue related to the company’s licensing …

  • ENSV: Enservco Reports 3Q; Capacity Expansion Program on Track Zacks Small Cap Research - Fri, Nov 14, 2014 8:00 AM EST

    In addition, management opportunistically acquired a package of oilfield service assets, including 12 hot oil trucks, a frac water heating unit and a 6-acre operating yard near Tioga, North Dakota in order to serve the northern Bakken Shale Region of the Williston Basin. Revenues of the Well Enhancement segment (hot oiling, …

  • CDTI: Restructuring debt schedule improves near term cash flow. Zacks Small Cap Research - Thu, Nov 13, 2014 10:00 PM EST

    By Ian Gilson, PhD, CFA NASDAQ:CDTI On Nov. 13, 2014 CDTi (NASDAQ:CDTI) agreed with its principle lender, and largest stockholder, Kanis S. A. to extend the maturity dates on several notes in return for ...

  • APDN: Price Target Adjusted Reflecting Recent Reverse Stock Split Zacks Small Cap Research - Thu, Nov 13, 2014 2:00 PM EST

    We adjust our price target for Applied DNA Sciences (APDN) to $12 per share reflecting the Company’s recent 1-for-60 reverse stock split. On October 29, 2014, APDN announced a 1-for-60 reverse split of its common stock.

  • Aastrom Fundamentals Continue To Improve Zacks Small Cap Research - Thu, Nov 13, 2014 1:30 PM EST

    We rates shares of Aastrom Biosciences, Inc. (ASTM) a 'Buy' and are adjusting our target to $6.50 per share. Based on industry-average multiples, we see Aastrom's stock doubling in 2015. On November 13, 2014, Aastrom Biosciences reported financial results for the quarter of 2014 ending September 30, 2014. Results in …

  • CYRX: UPS Deal A Major Revenue Opportunity Zacks Small Cap Research - Wed, Nov 12, 2014 3:15 PM EST

    By Brian Marckx, CFA OBB:CYRX Q2 2015 : CYRX Now Has Deals With "Big 3" Freight Carriers…   CryoPort Inc (OBB:CYRX) announced results for their 2015 fiscal second quarter ending September 30th.  ...

  • Media Frenzy Over InVivo's Device May Spark Rally In The Shares Zacks Small Cap Research - Wed, Nov 12, 2014 9:00 AM EST

    On Friday, November 7, 2014, we wrote an article providing a brief update on InVivo Therapeutics (NVIV). In the article, we noted that the first patient was enrolled in the company's pilot study of its Neuro-Spinal Scaffold (NSS) for the treatment of complete traumatic spinal cord injury on October 15, 2014. The subject, …

  • Zacks Upgrades AEMD to Buy Zacks Small Cap Research - Wed, Nov 12, 2014 8:00 AM EST

    Aethlon Medical (AEMD) filed their 10-Q for the fiscal second quarter ending 9/30/2014.  Revenue was $479k, well ahead of our $254k estimate as a result of AEMD recognizing more revenue from the year-3 contract during the quarter then we had anticipated.  In total, AEMD booked $445k in DARPA related revenue in Q2 (reflecting …

  • Don't Count Out Remoxy or Posidur Just Yet Zacks Small Cap Research - Wed, Nov 12, 2014 7:00 AM EST

    On November 3, 2014, Durect Corp. (DRRX) reported financial results for the third quarter ending September 30, 2014. For the first nine months of the year, revenues from ALZET Pumps and LACTLE Polymers totaled $8.1 million, a decline of 8% vs. the first nine months of 2013. Throughout 2014 Durect Corp continues to work …

  • On Nov. 1, 2014 S&W Seed Co. (SANW) announced its first fiscal quarter of 2015. Second quarter revenue guidance is $12 million.

  • Lipocine's Oral TRT Drug Too Attractive To Ignore Zacks Small Cap Research - Tue, Nov 11, 2014 10:30 AM EST

    On November 10, 2014 Lipocine (LPCN) reported financial results for the third quarter of 2014. The outcome of the meeting was decidedly negative for Clarus, with the committee not ready to recommend approval of Rextoro® at the current time.

  • Focus For Amarantus Remains On The Pipeline Zacks Small Cap Research - Mon, Nov 10, 2014 3:30 PM EST

    On November 10, 2014, 2014, Amarantus BioScience (AMBS) reported financial results for the third quarter 2014. Operating expenses included $1.899 million in R&D and $2.070 million in G&A. Net loss in the quarter totaled $4.399 million, or $0.01 per share based on an average share count outstanding of 767.7 million during …

  • VNRX: Clinical Data Supports CE Marking Runway Zacks Small Cap Research - Mon, Nov 10, 2014 3:10 PM EST

    As a reminder, the preliminary results announced in September came from the analysis of 938 patients from the ~4,800-patient retrospective colon cancer study being done in collaboration with Hvidovre Hospital at the University of Copenhagen in Denmark under the direction of Professor Hans Jorgen Nielsen (Professor of Surgical …

  • Tonix Pipeline Should Keep Rolling Forward In 2015 Zacks Small Cap Research - Mon, Nov 10, 2014 1:30 PM EST

    On November 10, 2014, Tonix Pharmaceuticals (TNXP) reported financial results for the third quarter for the period ending September 30, 2014. R&D expense has been tracking higher over the past few quarters as the company pushes forward with its two key pipeline products, TNX-102 SL and TNX-201. We expect R&D to decline …

  • BLFS: Record Product Sales, New Revenue Opportunities Zacks Small Cap Research - Mon, Nov 10, 2014 9:15 AM EST

    Relative to Somahlution, BLFS is in process of completing process engineering and validation work which the company expects to be completed by the end of the current year.  Manufacture of DuraGraft will then commence.  Revenue from manufacture of Somahlution's DuraGraft, which just received CE Marking for sale in Europe, …

  • Revenue was ahead of our revised estimates and of company guidance. Gross margins were essentially flat with the prior quarters whereas we had assumed some improvement.

  • Neuralstem Among Our 'Best for 2015' Biotech Names Zacks Small Cap Research - Fri, Nov 7, 2014 2:00 PM EST

    On November 7, 2014, Neuralstem Inc. (CUR) reported financial results for the third quarter ending September 30, 2014. As of September 30, 2014, Neuralstem reported cash and investments of approximately $27.2 million. Subsequent to the close of the third quarter, Neuralstem refinanced and increased its outstanding debt …

  • CEMI: Record DPP Sales, CLIA Waiver Zacks Small Cap Research - Fri, Nov 7, 2014 12:00 PM EST

    The third quarter saw several highlights for Chembio (CEMI), not the least of which was that international DPP sales set an all-time quarterly record.  This is the second consecutive quarter that international DPP sales were at a level that almost doubled that of the prior best quarter.  In addition, DPP sales accounted …

  • For InVivo, It's Finally About The Data Zacks Small Cap Research - Fri, Nov 7, 2014 12:00 PM EST

    On November 5, 2014, InVivo Therapeutics (NVIV) reported financial results for the third quarter ended September 30, 2014. The company did not report revenues during the quarter. We remind investors that on May 9, 2014, InVivo completed an underwritten public offering whereby the company sold 14.0 million shares of common …

  • Moving and Storage revenue was $833 million as compared to our estimate of $837 (both numbers include SAC management fees and other income less interest income). Operating income was the same as our estimate. Cash and cash equivalents increased from $495 million at year end 2014 and from $693 million at the end of the …

  • FDA Decision Nearing For Pozen Zacks Small Cap Research - Thu, Nov 6, 2014 3:00 PM EST

    On November 6, 2014, Pozen, Inc. (POZN) reported financial results for the third quarter ended June 30, 2014. Total revenues in the quarter were $7.5 million, comprised of $5.5 million in royalties on $43.2 million in sales of Vimovo at Horizon Pharma (HZNP) in the U.S.

  • Grupo TMM: 3Q14 Review & Looking Ahead to Mexico’s Energy Reforms Zacks Small Cap Research - Thu, Nov 6, 2014 10:40 AM EST

    Last week, Grupo TMM (GTMAY) reported results for the third quarter of 2014. We are raising our price target to $2.50 from $1.50.

  • Progress Continues At DARA Bio Zacks Small Cap Research - Thu, Nov 6, 2014 10:30 AM EST

    On November 5, 2014, DARA BioSciences, Inc. (DARA) reported financial results for the third quarter ended September 30, 2014. This was the second quarter in a row that DARA Bio exceeded Wall Street consensus revenue expectations.

  • Another Solid Quarter For Depomed Zacks Small Cap Research - Thu, Nov 6, 2014 10:05 AM EST

    On November 5, 2014, Depomed, Inc. (DEPO) reported financial results for the third quarter ended September 30, 2014. Going forward, we believe Cambia will see an acceleration in both prescriptions and sales thanks to limited competition – Cambia is the only non-triptan NSAID indicated for the acute treatment of migraine …

  • Dejour Energy: Drilling Program Continues at Kokopelli; 2 Wells Planned at Woodrush Zacks Small Cap Research - Thu, Nov 6, 2014 9:50 AM EST

    Progress continues at the Kokopelli Project, in which Dejour Energy (DEJ) holds a 25% working interest. According to filings with COGIS (Colorado Oil and Gas Information System), the first two wells (Federal 14-15-1-21 and Federal 14-15-2-21) of Phase 2 at Kokopelli have been drilled and the third (Federal 14-15-3-21) …

  • Threshold: A Biopharmaceutical Company focused on Hypoxia-targeted Cancer Therapy Zacks Small Cap Research - Thu, Nov 6, 2014 9:00 AM EST

    Threshold Reports 3Q14 Financials, Current Cash Can Run into 2017 Both revenues were generated form the amortization of the aggregate of $110 million in upfront payment and milestone payments from the Company’s (THLD) collaborator Merck KGaA.   The increase was due primarily to an increase in clinical development expenses …

  • CBMX: Record Testing Volumes and Revenue Zacks Small Cap Research - Wed, Nov 5, 2014 4:00 PM EST

    CombiMatrix Corp (CBMX) announced financial results for the third quarter ending September 30th on November 4th.  Revenue was in-line with our estimate (which we upwardly revised following the company's 10/7/14 preannouncement) while operating expenses came in slightly better than our numbers.  The beat on operating expense …

  • Important Data From Protalex Coming In December 2014 Zacks Small Cap Research - Wed, Nov 5, 2014 3:45 PM EST

    On October 8, 2014, Protalex, Inc. (PRTX) filed its Form 10K for the first quarter fiscal 2015, which was the three month period that ended August 31, 2014. As expected, Protalex did not report any revenues in the quarter. The last time Protalex raised money was in January 2014 through a private offering of 0.471 million …

  • Phase 3 Kiacta Study Chugging Along Nicely For Bellus Health Zacks Small Cap Research - Wed, Nov 5, 2014 12:45 PM EST

    On November 5, 2014, Bellus Health, Inc. (BLU.TO) (BLUSF) reported financial results for the third quarter of 2014. Patients were stratified according to nephrotic status, with a classification of nephrotic requiring a 24-hour urinary excretion of more than 3 g of protein, a serum albumin concentration of less than 3.4 …

  • CDTI: Company sells stock and warrants. Zacks Small Cap Research - Wed, Nov 5, 2014 9:00 AM EST

    By Ian Gilson, PhD, CFA NASDAQ:CDTI CDTi (NASDAQ:CDTI) announced on Nov. 04, 2014 that it has sold 1.385 million common shares, series A warrants (an aggregate of 388,393 shares) and series B warrants ...

Next >>